Article
Brochure
Executive Resource
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- ESG Strategy & Consulting
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Transaction Advisory
- Trust & Estate
- Valuation
Although the SEC withdrew its climate disclosure rule, state and international regulations still require businesses to manage emissions and climate risks.
Wyoming House Bill 11 expands the manufacturing sales and use tax exemptions. We break down what this means for businesses operating in Wyoming.
Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.
Learn how HMRC's guidelines impact transfer pricing for life sciences and other multinationals and how to mitigate risks and ensure compliance.
Establishing effective ESG KPIs is critical in today’s complex environment. We outline key considerations to drive sustainable success.
Weaver conducted a climate risk analysis to assess and mitigate natural disaster impacts, ensuring resilience and sustainability in our U.S. locations.
The National Association of Manufacturers (NAM) has released its Q4 Manufacturers’ Survey. Learn more about what it means for leadership in 2025.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.
Boost e-commerce success with strategic planning, profit tracking and dynamic pricing to drive growth, efficiency and long-term profitability.
Beneficial Ownership Information (BOI) reporting, a mandate of the Corporate Transparency Act (CTA), continues to be complicated.
New York’s business interruption law introduced new stand-alone coverage opportunities, providing businesses options for tailored protection.
